arrow_rightarrow_righticon_excelicon_pficon_ppticon_wordmagnifier

Monday 11 March

Monday 11 Mar

Session 7: Future of primary rectal cancer treatment

08:15

Role of external boost and brachytherapy in rectal cancer

Maaike Berbeé, the Netherlands

08:35

Challenges in rectal cancer surgery; which problems have to be solved?

Roel Hompes, the Netherlands

08:55

Locally recurrent rectal cancer; multimodality approach

Quentin Denost, France

09:15

Discussion

Session 8: Systemic therapy in the metastatic setting – state of the art and future 

09:30

Targeting RAS mutated tumors

Volker Heineman, Germany

09:50

Prognostic/predictive value of molecular and clinical factors: What makes the difference?

Teresa Macarulla, Spain

10:10

Feasibility and outcomes of a national expert panel of liver surgeons to determine secondary resectability in patients with initially unresectable colorectal liver metastases

Karen Bolhuis, the Netherlands

10:30

Discussion

10:45

Break

Session 9: Colorectal cancer and the immune system

11:15

What are the new drugs in the field of immunotherapy?

Guillem Argiles, Spain

11:35

What are the diagnostic tools and novel concepts of cancer evolution?

Jerome Galon, France

11:55

What are the effects that are interfering with local or current treatments?

12:15

Discussion

12:45

Lunch & Poster viewing

CRC Group Meetings / trial Meetings / Consensus or guideline initiatives

12:45

Prospective Dutch CRC cohort (PLCRC): Nationwide infrastructure for colorectal cancer research in the Netherlands

Geraldine Vink, the Netherlands

12:45

Best abstracts

Session 10: Genetics

14:00

Update: the genetic differential diagnosis of polyposis and CRC

Maartje Nielsen, the Netherlands

14:20

Predicting CRC risk: from tumor syndromes genes to polygenic risk scores

Richard Houlston, United Kingdom

14:40

Chemoprevention and vaccines for hereditary CRC

Matthias Kloor, Germany

15:00

Discussion

15:15

Break

Session 11: Curative treatment of metastases

15:45

Controversies in loco-regional therapy of peritoneal metastases: What is really needed?

Niels Kok, the Netherlands

16:05

Liver-directed therapies (Hepatic arterial infusion, SIRT): What to use when?

Bas Groot Koerkamp, the Natherlands

16:25

Spectrum of treatments for lung metastases: SBRT, RFA, resection or no local therapy at all?

Dirk Van Raemdonck, belgium

16:45

Discussion

17:00

Closing and drinks